Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia
Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia: An Ambidirectional Patient-Control Cohort Study
To collect large-scale multimodal data, including genomic information, neuroimaging, neurophysiological measures, cognitive assessments, and clinical characteristics from stroke survivors and healthy controls.
This study aims to develop and validate an integrated prediction model for identifying individuals at high risk of post-stroke vascular dementia and to establish a foundation for precision medicine approaches in stroke-related cognitive impairment.
研究概览
地位
条件
详细说明
This study aims to establish a comprehensive multimodal dataset integrating genomic information, clinical characteristics, neuroimaging, neurophysiological measures, and longitudinal cognitive assessments in stroke survivors and cognitively healthy controls. The study includes participants from the subacute to chronic stages after stroke and follows them longitudinally to capture changes in cognitive and functional outcomes over time.
By combining whole genome sequencing, magnetic resonance imaging (MRI), electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), and clinical assessments, the study seeks to characterize factors associated with cognitive decline and vascular dementia following stroke.
The collected data will be used to develop and validate an integrated multimodal prediction model capable of identifying individuals at elevated risk of post-stroke vascular dementia. The findings are expected to improve risk stratification, support individualized monitoring and intervention strategies, and contribute to the development of precision medicine approaches for stroke survivors.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Seyoung Shin, MD
- 电话号码：+82437505000
- 邮箱：seyoung0706@chamc.co.kr
学习地点
-
-
Gyeonggi-do
-
Gyeonggi-do、Gyeonggi-do、韩国、13497
- 招聘中
- Bundang CHA Medical Center
-
接触：
- Seyoung Shin, MD
- 电话号码：+82427305000
- 邮箱：seyoung0706@chamc.ac.kr
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
Healthy Control Group:
- Adults aged 19 years or older.
- Able to be age- and sex-matched to the stroke cohort.
- No history of stroke, transient ischemic attack (TIA), or other central nervous system disorders.
- Cognitive function within the normal range for age and education level based on screening assessments (K-MMSE and K-MoCA).
- Able to understand the study procedures and provide written informed consent.
Stroke Patient Group:
- Adults aged 19 years or older.
- First-ever ischemic or hemorrhagic stroke confirmed by CT or MRI.
- Enrolled in one of the following strata according to time since stroke onset:
Stratum A: 7 days to 3 months after stroke onset. Stratum B: >3 months to 12 months after stroke onset. Stratum C: >12 months to 36 months after stroke onset.
- Able to understand the study procedures and provide written informed consent, or consent provided by a legally authorized representative when applicable.
Exclusion Criteria:
Healthy Control Group:
- Current severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications.
- Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL).
- Severe medical illness considered inappropriate for study participation.
- Any condition that, in the opinion of the investigator, would make participation unsuitable.
Stroke Patient Group:
- Impaired ability to provide consent (MMSE <10) without an accompanying caregiver or legally authorized representative.
- History of dementia due to causes other than stroke (e.g., Alzheimer's disease) prior to stroke onset.
- History of major neurological disorders affecting cognition prior to stroke onset (e.g., Parkinson's disease, brain tumor, multiple sclerosis).
- Severe aphasia or impaired consciousness preventing completion of cognitive assessments.
- Current or pre-stroke severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications.
- Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL).
- Contraindication to MRI (e.g., metallic implants) or refusal to provide blood samples for genomic analysis.
- Any condition that, in the opinion of the investigator, would make participation unsuitable.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
Stroke patients
Adults aged 19 years or older with first-ever ischemic or hemorrhagic stroke.
Participants may be enrolled during the subacute or chronic stage after stroke and will undergo genomic, neuroimaging, neurophysiological, cognitive, and functional assessments with longitudinal follow-up for up to 36 months.
|
|
Healthy controls
Cognitively normal adults aged 19 years or older without a history of stroke, transient ischemic attack, or other major central nervous system disorders.
Participants will undergo genomic, neuroimaging, neurophysiological, cognitive, and functional assessments and follow-up evaluations.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mini Mental Status Examination
大体时间：Baseline to 36 months
|
Mini Mental State Examination is a 30-question assessment of cognitive function that evaluates attention and orientation, memory, registration, recall, calculation, language, and ability to draw a complex polygon (range 0-30).
Higher scores indicate better cognitive function.
|
Baseline to 36 months
|
|
Korean Montreal Cognitive Assessment
大体时间：Baseline to 36 months
|
The Korean Montreal Cognitive Assessment is a cognitive screening tool designed to detect mild cognitive impairment.
It evaluates multiple cognitive domains including attention, executive function, memory, language, visuospatial ability, abstraction, calculation, and orientation (range 0-30).
Higher scores indicate better cognitive function.
|
Baseline to 36 months
|
|
Clinical Dementia Rating
大体时间：Baseline to 36 months
|
The Clinical Dementia Rating is a clinician-rated scale used to assess the severity of cognitive impairment and dementia across six domains including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care (range 0-3).
Higher scores indicate greater cognitive impairment and worse outcomes.
|
Baseline to 36 months
|
|
Functional Ambulation Category
大体时间：Baseline to 36 months
|
The Functional Ambulation Categories is a 5-point functional walking test that evaluates ambulation ability, determining how much human support the patient requires when walking, regardless of whether or not they use a personal assistive device (range 0-5).
Higher scores indicate greater independence in ambulation.
|
Baseline to 36 months
|
|
Modified Barthel Index
大体时间：Baseline to 36 months
|
The Modified Barthel Index is a scale used to measure disability or dependence in activities of daily living in stroke survivors (range 0-100).
Higher scores indicate greater independence in activities of daily living.
|
Baseline to 36 months
|
|
Berg Balance Scale
大体时间：Baseline to 36 months
|
The Berg Balance Scale is a 14-item performance-based measure used to assess static and dynamic balance abilities and risk of falling in individuals with neurological disorders (range 0-56).
Higher scores indicate better balance performance and lower risk of falling.
|
Baseline to 36 months
|
|
Electroencephalography Delta-Alpha Ratio
大体时间：Baseline to 36 months
|
The delta-alpha ratio (DAR) is a quantitative electroencephalographic measure calculated as delta power divided by alpha power.
Higher DAR values indicate greater electroencephalography slowing and are associated with impaired brain function.
|
Baseline to 36 months
|
|
Electroencephalography Functional Connectivity Index
大体时间：Baseline to 36 months
|
Functional connectivity indices derived from electroencephalography recordings to assess connectivity between brain regions and overall brain network organization.
|
Baseline to 36 months
|
|
Functional Near-Infrared Spectroscopy (fNIRS)
大体时间：Baseline to 36 months
|
Functional near-infrared spectroscopy is a non-invasive neuroimaging technique used to assess cortical activation by measuring changes in oxygenated and deoxygenated hemoglobin during task performance.
|
Baseline to 36 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.